Avastin breast cancer drug receives EU support
Mar 4, 2011
The controversial breast cancer drug Avastin, produced by Swiss biotech company Roche, has received European Union support, according to Market Watch.
Avastin is scheduled to receive a second hearing from the U.S. Food and Drug Administration (FDA), before the organization decides whether or not to support the drug for breast cancer use. Avastin is currently supported by the FDA for other cancers such as colon cancer.
"We are pleased that the European Commission is continuing to support Avastin in combination with [chemotherapy]. This is important news for thousands of women living with incurable ...breast cancer in the European Union," said Hal Barron, Roche's chief medical officer.
Roche is scheduled to received a second hearing from the FDA in June of 2011, in order to determine "safety and efficacy," concerning the drug's use for metastatic breast cancer, according to the Wall Street Journal.
Roche, which owns Genentech in the U.S., produces drugs related to oncology, virology, inflammation and metabolism, among other areas. Avastin had a net sale of $6.9 billion in 2010, making it the most profitable drug for Roche, according to Market Watch.